AnselmiAGaudinoMRisalvatoNLauriaGGliecaF. Asymptomatic carotid artery disease in valvular heart surgery: impact of systematic screening on surgical strategy and neurological outcome. Angiology. 2011 (in press);
2.
UrbinatiSDi PasqualeGAndreoliA. Frequency and prognostic significance of silent coronary artery disease in patients with cerebral ischemia undergoing carotid endarterectomy. Am J Cardiol. 1992;69(14):1166–1170.
3.
ParaskevasKIMikhailidisDPLiapisCD. Internal carotid artery occlusion: association with atherosclerotic disease in other arterial beds and vascular risk factors. Angiology. 2007;58(3):329–335.
4.
KawaradaOYokoiYMoriokaN. Carotid stenosis and peripheral artery disease in Japanese patients with coronary artery disease undergoing coronary artery bypass grafting. Circ J. 2003;67(12):1003–1006.
5.
KaranjiaPNMaddenKPLobnerS. Coexistence of abdominal aortic aneurysm in patients with carotid stenosis. Stroke. 1994;25(3):627–630.
6.
Mortaz HejriSMostafazadeh DavaniBSahraianMA. Carotid endarterectomy for carotid stenosis in patients selected for coronary artery bypass graft surgery. Cochrane Database Syst Rev. 2009;4:CD006074.
7.
SgorbiniLScuteriALeggioMLeggioF. Association of mitral annulus calcification, aortic valve calcification with carotid intima media thickness. Cardiovasc Ultrasound. 2004;2:19.
8.
SoyluMDemirADOzdemirOYzunYKorkmazS. Relationship between plaque morphology of carotid artery and aortic valve calcification. Angiology. 2003;54(6):637–640.
9.
TziomalosKAthyrosVGKaragiannisAMikhailidisDP. Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?. Expert Opin Ther Targets. 2008;12(7):809–820.
10.
ParaskevasKILiapisCDHamiltonGMikhailidisDP. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?. Eur J Vasc Endovasc Surg. 2006;32(3):286–293.
11.
OostergaMVoorsAAPintoYM. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol. 2001;87(5):542–546.
12.
Kjøller-HansenLSteffensenRGrandeP. Effect of ramipril on postrevascularization prevalence of angina and quality of life. Int J Cardiol. 2004;95(2-3):159–165.
13.
ChanAYMcAlisterFANorrisCM. Alberta provincial program for outcome assessment in coronary heart disease (APPROACH) Investigators. Effect of beta-blocker use on outcomes after discharge in patients who underwent cardiac surgery. J Thorac Cardiovasc Surg. 2010;140(1):182–187.
14.
YoshiokaISakuraiMNamaiAKawamuraT. Postoperative treatment of carvedilol following low dose landiolol has preventive effect for atrial fibrillation after coronary artery bypass grafting. Thorac Cardiovasc Surg. 2009;57(8):464–467.
15.
LazarHL. All coronary artery bypass graft surgery patients will benefit from angiotensin-converting enzyme inhibitors. Circulation. 2008;117(1):6–8.
16.
AroraRSowersJRSaundersEProbstfieldJLazarHL. Cardioprotective strategies to improve long-term outcomes following coronary artery bypass surgery. J Card Surg. 2006;21(2):198–204.
17.
NovaroGMTiongIYPearceGLLauerMSSprecherDLGriffinBP. Effect of hydroxylmethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001;104(18):2205–2209.
18.
AronowWSAhnCKronzonIGoldmanME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001;88(6):693–695.
19.
RosenhekRRaderFLohoN. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2001;110(10):1291–1295.
20.
HelskeSKupariMLindstedtKAKovanenPT. Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol. 2007;18(5):483–491.
21.
ToliKParaskevasKIPoulakouMV. Association between plasma levels and immunolocalization of cytokines in heart valve lesions: a possible target for treatment?. Expert Opin Ther Targets. 2008;12(10):1209–1215.
22.
EdwardsJEMooreRA. Statins in hypercholesterolemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract. 2003;4:18.
23.
CurranMPGoaKL. Lovastatin extended release: a review of its use in the management of hypercholesterolemia. Drugs. 2003;63(7):685–699.
24.
WierzbickiAS. Lipid-altering therapies and the progression of atherosclerotic disease. Cardiovasc Intervent Radiol. 2007;30(2):155–160.
25.
RosensonRS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis. 2004;173(1):1–12.
26.
ChanKLTeoKDumesnilJGNiATamJASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121(2):306–314.
27.
RosseboABPedersenTRBomanK. SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–1356.
28.
HolmeIBomanKBrudiP. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am J Cardiol. 2010;105(12):1802–1808.
29.
ShavelleDMTakasuJBudoffMJMaoSZhaoXQO’BrienKD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002;359(9312):1125–1126.
30.
PohleKMaffertRRopersD. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 2001;104(16):1927–1932.
31.
Antonini-CanterinFZuppiroliAPopescuBA. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol. 2003;92(12):1479–482.
32.
Antonini-CanterinFZuppiroliABaldessinFPopescuBANicolosiGL. Is there a role of statins in the prevention of aortic biological prostheses degeneration?. Cardiovasc Ultrasound. 2006;4:26.
33.
VermaSSzmitkoPEFedakPWErrettLLatterDADavidTE. Can statin therapy alter the natural history of bicuspid aortic valves?. Am J Physiol Heart Circ Physiol. 2005;288(6):H2547–H2549.
34.
EjiriJInoueNTsukubeT. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res. 2003;59(4):988–996.
35.
NagashimaHAokaYSakomuraY. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg. 2002;36(1):158–163.
36.
SteinmetzEFBuckleyCShamesML. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg. 2005;241(1):92–101.
37.
TsiaraSElisafMMikhailidisDP. Early vascular benefits of statin therapy. Curr Med Res Opin. 2003;19(6):540–556.
38.
ChelloMGoffredoCPattiG. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cardiothorac Surg. 2005;28(6):805–810.
39.
TjangYSvan HeesYKorferRGrobbeeDEvan der HeijdenGJ. Predictors of mortality after aortic valve replacement. Eur J Cardiothorac Surg. 2007;32(3):469–474.
40.
TonelliM. The effect of statins on preservation of kidney function in patients with coronary artery disease. Curr Opin Cardiol. 2006;21(6):608–612.
41.
AlnaebMEYoussefFMikhailidisDPHamiltonG. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology. 2006;57(1):65–71.
42.
AgarwalR. Effect of statins on renal function. Am J Cardiol. 2006;97(5):748–755.
43.
KapurNK. Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Rev Cardiovasc Ther. 2007;5(2):161–175.
44.
BittnerV. Perspectives on dyslipidemia and coronary heart disease in women: an update. Curr Opin Cardiol. 2006;21(6):602–607.
45.
ParaskevasKIGiannoukasADKotsikorisIMikhailidisDP. Contrast-induced nephropathy and the vascular patient. Angiology. 2010;61(8):721–723.
46.
NaylorARMehtaZRothwellPMBellPR. Carotid artery disease and stroke during coronary artery bypass: a critical review of the literature. Eur J Vasc Endovasc Surg. 2002;23(4):283–294.
47.
NaylorARBownMJ. Stroke after cardiac surgery and its association with asymptomatic carotid disease: an updated systematic review and meta-analysis. Eur J Vasc Endovasc Surg2011;41(5):607–624.
48.
BorgerMA. Preventing stroke during coronary bypass: are we focusing on the wrong culprit?. J Card Surg. 2005;20(1):58–59.
49.
ParolariATremoliECavallottiL. Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis?. Heart. 2011;97(7):523–529.
50.
GilmanovDBevilacquaSMazzoneAGlauberM. Do statins slow the process of calcification of aortic tissue valves?. Interact Cardiovasc Thorac Surg. 2010;11(3):297–301.
51.
ParaskevasKIMikhailidisDP. Statins may not prevent structural valve degeneration of aortic bioprosthetic valves, but should probably be prescribed to patients undergoing heart valve surgery nonetheless. Interact Cardiovasc Thorac Surg. 2010;11(3):302.
